Compare JAZZ & AVAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | AVAV |
|---|---|---|
| Founded | 2003 | 1971 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Aerospace |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 11.3B |
| IPO Year | 2007 | 2006 |
| Metric | JAZZ | AVAV |
|---|---|---|
| Price | $194.31 | $180.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 17 |
| Target Price | $216.92 | ★ $316.88 |
| AVG Volume (30 Days) | 734.6K | ★ 1.1M |
| Earning Date | 05-05-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,618,693,000.00 | N/A |
| Revenue This Year | $6.13 | $135.55 |
| Revenue Next Year | $7.75 | $14.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $98.96 | $138.00 |
| 52 Week High | $200.24 | $417.86 |
| Indicator | JAZZ | AVAV |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 39.74 |
| Support Level | $159.78 | $175.42 |
| Resistance Level | $198.00 | $282.15 |
| Average True Range (ATR) | 4.75 | 8.98 |
| MACD | 0.67 | 1.55 |
| Stochastic Oscillator | 69.84 | 32.42 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
AeroVironment Inc supplies unmanned aircraft systems, tactical missile systems, high-altitude pseudo-satellites, and other related services to government agencies within the United States Department of Defense as well as the United States allied international governments. The systems can help with security, surveillance, or sensing, and provide eyes in the sky without needing an actual person, or driver in the sky. The company is a defense technology provider delivering integrated capabilities across air, land, sea, space, and cyber. It develops and deploy autonomous systems, precision strike systems, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities. Company operates in three segments: UxS, LMS, MW.